FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024969918> ?p ?o ?g. }

• W2024969918 endingPage "5683" @default.
• W2024969918 startingPage "5673" @default.
• W2024969918 abstract "Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. We have previously shown that Apo2 ligand/TNF-Related apoptosis inducing ligand (Apo2L/TRAIL) induces apoptosis of MM cells, including cells either sensitive or resistant to Dex and cytotoxic drugs, and overcomes the growth and survival effect of IL-6; conversely, NF-kappaB transcriptional activity attenuates their Apo2L/TRAIL-sensitivity. In the current study, we demonstrate that IGF-1 stimulates sustained activation of NF-kappaB and Akt; induces phosphorylation of the FKHRL-1 Forkhead transcription factor; upregulates a series of intracellular anti-apoptotic proteins including FLIP, survivin, cIAP-2, A1/Bfl-1, and XIAP; and decreases Apo2L/TRAIL-sensitivity of MM cells. In contrast, IL-6 does not cause sustained NF-kappaB activation, induces less pronounced Akt activation and FKHRL-1 phosphorylation than IGF-1, and increases the expression of only survivin. Forced overexpression of constitutively active Akt in MM-1S cells reduced their sensitivity to Apo2L/TRAIL and to doxorubicin (Doxo). In contrast, the Akt inhibitor IL-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate induced cell death of both Dex- and Doxo-sensitive and -resistant cells; opposed the protective effect of constitutive Akt activity against Apo2L/TRAIL; and abrogated the NF-kappaB activation, increase of anti-apoptotic proteins and protection against Apo2L/TRAIL induced by IGF-1. These findings therefore define an important role of the Akt pathway in modulating tumor cell responsiveness to Apo2L/TRAIL, delineate molecular mechanisms for the survival effects of IGF-1, and characterize differential pathophysiologic sequelae of IGF-1 vs IL-6 on MM cells. Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1." @default.
• W2024969918 created "2016-06-24" @default.
• W2024969918 creator A5006765393 @default.
• W2024969918 creator A5008159204 @default.
• W2024969918 creator A5010021766 @default.
• W2024969918 creator A5012712111 @default.
• W2024969918 creator A5027328800 @default.
• W2024969918 creator A5032464400 @default.
• W2024969918 creator A5043526996 @default.
• W2024969918 creator A5044162398 @default.
• W2024969918 creator A5045740077 @default.
• W2024969918 creator A5081299017 @default.
• W2024969918 creator A5091207345 @default.
• W2024969918 date "2002-08-13" @default.
• W2024969918 modified "2023-10-16" @default.
• W2024969918 title "Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications" @default.
• W2024969918 cites W1494568828 @default.
• W2024969918 cites W1535042563 @default.
• W2024969918 cites W1565618380 @default.
• W2024969918 cites W1904788586 @default.
• W2024969918 cites W1921204171 @default.
• W2024969918 cites W1926301789 @default.
• W2024969918 cites W1965583590 @default.
• W2024969918 cites W1983398917 @default.
• W2024969918 cites W1993772406 @default.
• W2024969918 cites W1999954329 @default.
• W2024969918 cites W2007998678 @default.
• W2024969918 cites W2010035812 @default.
• W2024969918 cites W2021413266 @default.
• W2024969918 cites W2030447859 @default.
• W2024969918 cites W2042854276 @default.
• W2024969918 cites W2044825593 @default.
• W2024969918 cites W2052376299 @default.
• W2024969918 cites W2056217426 @default.
• W2024969918 cites W2058580930 @default.
• W2024969918 cites W2070739194 @default.
• W2024969918 cites W2085233944 @default.
• W2024969918 cites W2087835234 @default.
• W2024969918 cites W2105441981 @default.
• W2024969918 cites W2106284224 @default.
• W2024969918 cites W2115207474 @default.
• W2024969918 cites W2130988210 @default.
• W2024969918 cites W2135416318 @default.
• W2024969918 cites W2142149038 @default.
• W2024969918 cites W2160121103 @default.
• W2024969918 cites W2162628305 @default.
• W2024969918 cites W2165980203 @default.
• W2024969918 cites W2169295136 @default.
• W2024969918 cites W2169724245 @default.
• W2024969918 cites W2330709458 @default.
• W2024969918 cites W4230408070 @default.
• W2024969918 cites W4231649703 @default.
• W2024969918 cites W4235388496 @default.
• W2024969918 cites W4313335080 @default.
• W2024969918 cites W4366065638 @default.
• W2024969918 cites W82814575 @default.
• W2024969918 doi "https://doi.org/10.1038/sj.onc.1205664" @default.
• W2024969918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12173037" @default.
• W2024969918 hasPublicationYear "2002" @default.
• W2024969918 type Work @default.
• W2024969918 sameAs 2024969918 @default.
• W2024969918 citedByCount "454" @default.
• W2024969918 countsByYear W20249699182012 @default.
• W2024969918 countsByYear W20249699182013 @default.
• W2024969918 countsByYear W20249699182014 @default.
• W2024969918 countsByYear W20249699182015 @default.
• W2024969918 countsByYear W20249699182016 @default.
• W2024969918 countsByYear W20249699182017 @default.
• W2024969918 countsByYear W20249699182018 @default.
• W2024969918 countsByYear W20249699182019 @default.
• W2024969918 countsByYear W20249699182020 @default.
• W2024969918 countsByYear W20249699182021 @default.
• W2024969918 countsByYear W20249699182022 @default.
• W2024969918 countsByYear W20249699182023 @default.
• W2024969918 crossrefType "journal-article" @default.
• W2024969918 hasAuthorship W2024969918A5006765393 @default.
• W2024969918 hasAuthorship W2024969918A5008159204 @default.
• W2024969918 hasAuthorship W2024969918A5010021766 @default.
• W2024969918 hasAuthorship W2024969918A5012712111 @default.
• W2024969918 hasAuthorship W2024969918A5027328800 @default.
• W2024969918 hasAuthorship W2024969918A5032464400 @default.
• W2024969918 hasAuthorship W2024969918A5043526996 @default.
• W2024969918 hasAuthorship W2024969918A5044162398 @default.
• W2024969918 hasAuthorship W2024969918A5045740077 @default.
• W2024969918 hasAuthorship W2024969918A5081299017 @default.
• W2024969918 hasAuthorship W2024969918A5091207345 @default.
• W2024969918 hasBestOaLocation W20249699181 @default.
• W2024969918 hasConcept C104317684 @default.
• W2024969918 hasConcept C11960822 @default.
• W2024969918 hasConcept C127561419 @default.
• W2024969918 hasConcept C190283241 @default.
• W2024969918 hasConcept C2775975398 @default.
• W2024969918 hasConcept C2777408456 @default.
• W2024969918 hasConcept C31573885 @default.
• W2024969918 hasConcept C33195913 @default.
• W2024969918 hasConcept C502942594 @default.
• W2024969918 hasConcept C55493867 @default.
• W2024969918 hasConcept C62478195 @default.

• next